Investment Stage

Focus Areas

About Investor

Nihal Sinha is a Partner at F-Prime Capital Partners based in London and focused on biotechnology investing. He works with innovative life science companies across Seed, Series A, and Series B funding stages. His interests include therapeutic development, biotechnology platforms, and scientific innovations capable of transforming healthcare outcomes. Nihal partners closely with founders and research teams to help advance promising technologies toward commercialization. He typically invests between $1 million and $15 million, with an average investment size around $7 million, making him one of the larger check writers within the biotech team. Companies developing breakthrough therapies or advanced biotechnology solutions would likely be highly relevant to his investment focus.